Novartis Entresto® granted expanded indication in chronic heart failure by FDA
16 févr. 2021 13h23 HE
|
Novartis International AG
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction...
Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
29 janv. 2021 12h05 HE
|
Novartis International AG
Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is based on...
En 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments
26 janv. 2021 01h00 HE
|
Novartis International AG
Chiffre d’affaires net des activités poursuivies1 en hausse de 3% (tcc2, +3% USD): Pharmaceuticals: cette unité opérationnelle a progressé de 5% (tcc), soutenue par Entresto...
Novartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben
26 janv. 2021 01h00 HE
|
Novartis International AG
Der Nettoumsatz der fortzuführenden Geschäftsbereiche¹ stieg im Geschäftsjahr um 3% (kWk², +3% USD): Die Geschäftseinheit Pharmaceuticals wuchs um 5% (kWk), wozu vor allem Entresto (+44% kWk),...
Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
26 janv. 2021 01h00 HE
|
Novartis International AG
Full year net sales from continuing operations¹ up 3% (cc², +3% USD): Pharmaceuticals BU grew 5% (cc) driven by Entresto (+44% cc), Zolgensma (reaching USD 0.9 billion), Cosentyx (+13%...
Novartis receives complete response letter from U.S. FDA for inclisiran
18 déc. 2020 16h50 HE
|
Novartis International AG
The U.S. Food and Drug Administration (FDA) has not raised any concerns related to the efficacy or safety of inclisiran. The complete response letter is due to unresolved facility inspection-related...
Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event
24 nov. 2020 01h00 HE
|
Novartis International AG
Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth...
Novartis au T3: performance solide, croissance de 11% du résultat opérationnel core, chiffre d’affaires net proche de l’an dernier, pipeline en fort progrès; hausse du résultat opérationnel core prévu
27 oct. 2020 02h00 HE
|
Novartis International AG
Chiffre d’affaires net des activités poursuivies1 au T3 en ligne avec celui de l’exercice précédent (tcc2, +1% USD): Les moteurs de la croissance ont été notamment Entresto USD 632 millions (+45%...
Novartis im 3. Qu. mit solider Performance: operatives Kernergebnis steigt um 11%, Nettoumsatz auf Vorjahresniveau, starke Pipeline-Fortschritte; Jahresprognose für operatives Kernergebnis angehoben
27 oct. 2020 02h00 HE
|
Novartis International AG
Im dritten Quartal 2020 lag der Nettoumsatz der fortzuführenden Geschäftsbereiche1 auf dem Niveau des Vorjahres (kWk2, +1% USD): Zu den Wachstumsträgern gehörten Entresto (USD 632 Millionen,...
Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.
27 oct. 2020 02h00 HE
|
Novartis International AG
Q3 net sales from continuing operations1 were in line with prior year (cc2, +1% USD): Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1...